The Nationwide Austrian Registry: a prospective data collection on epidemiology; therapy and outcome of invasive mould infections in immunocompromised and/or immunosuppressed patients

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés. The Nationwide Austrian Registry: a prospective data collection on epidemiology; therapy and outcome of invasive mould infections in immunocompromised and/or immunosuppressed patients S. Perkhofer, C. Lass-Flörl, M. Hell, G. Russ, R. Krause, M. Hönigl, C. Geltner, J. Auberger, G. Gastl, M. Mitterbauer, et al.

[1]  R. Porcher,et al.  High rate of breakthrough invasive aspergillosis among patients receiving caspofungin for persistent fever and neutropenia. , 2010, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[2]  C. Lass‐Flörl.  The changing face of epidemiology of invasive fungal disease in Europe , 2009, Mycoses.

[3]  E. Anaissie,et al.  Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  H. Einsele,et al.  Significant alterations in the epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies , 2008, International journal of hematology.

[5]  J. Perfect,et al.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  Raoul Herbrecht,et al.  Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  E. Anaissie,et al.  Presentation of the PATH Alliance registry for prospective data collection and analysis of the epidemiology, therapy, and outcomes of invasive fungal infections. , 2007, Diagnostic microbiology and infectious disease.

[8]  G. Wassmer,et al.  A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML). , 2007, The Journal of infection.

[9]  G. Gastl,et al.  The value of computed tomography-guided percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised patients. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  Matt Post,et al.  Invasive fungal infections in allogeneic and autologous stem cell transplant recipients: a single‐center study of 166 transplanted patients , 2007, Transplant infectious disease : an official journal of the Transplantation Society.

[11]  C. Lass‐Flörl,et al.  Primary antifungal prophylaxis in leukaemia patients , 2007 .

[12]  J. Mehta,et al.  Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy , 2007, Bone Marrow Transplantation.

[13]  J. Perfect,et al.  Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. , 2007, The New England journal of medicine.

[14]  K. Marr,et al.  Emergence of opportunistic mould infections in the hematopoietic stem cell transplant patient , 2006, Current infectious disease reports.

[15]  O. Cornely,et al.  HPLC analysis of the antifungal agent posaconazole in patients with haematological diseases , 2006, Mycoses.

[16]  J. Fung,et al.  Zygomycosis in Solid Organ Transplant Recipients in a Tertiary Transplant Center and Review of the Literature , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[17]  C. Viscoli,et al.  Empirical antifungal therapy in patients with neutropenia and persistent or recurrent fever of unknown origin , 2006, British journal of haematology.

[18]  M. Dierich,et al.  Epidemiology and outcome of infections due to Aspergillus terreus: 10‐year single centre experience , 2005, British journal of haematology.

[19]  T. Patterson.  Advances and challenges in management of invasive mycoses , 2005, The Lancet.

[20]  P. Pappas.  Amphotericin B lipid complex in the treatment of invasive fungal infections: results of the Collaborative Exchange of Antifungal Research (CLEAR), an industry-supported patient registry. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  Russell E. Lewis,et al.  Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. , 2005, The Journal of infectious diseases.

[22]  Nina Singh,et al.  Aspergillus Infections in Transplant Recipients , 2005, Clinical Microbiology Reviews.

[23]  O. Lortholary,et al.  A multicentre pharmacoepidemiological study of therapeutic practices in invasive fungal infections in France during 1998-1999. , 2004, The Journal of antimicrobial chemotherapy.

[24]  W. Leisenring,et al.  Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. , 2004, Blood.

[25]  Richard Sylvester,et al.  Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. , 2002, The New England journal of medicine.

[26]  Lawrence Corey,et al.  Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  E. Anaissie,et al.  Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. , 2002, The New England journal of medicine.

[28]  Nina Singh,et al.  Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  E. Anaissie.  Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[30]  M. Pfaller.  Epidemiological typing methods for mycoses. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  M. Okudaira,et al.  Fungal infections in cancer patients: An international autopsy survey , 1992, European Journal of Clinical Microbiology and Infectious Diseases.

[32]  J. Aisner,et al.  Treatment of invasive aspergillosis: relation of early diagnosis and treatment to response. , 1977, Annals of internal medicine.

[33]  K. Engels,et al.  Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. , 2010, The Journal of infection.

[34]  C. Kauffman,et al.  Changing epidemiology of rare mould infections: implications for therapy. , 2007, Drugs.

[35]  D. Subirá,et al.  Aspergillus fumigatus: a rare cause of vertebral osteomyelitis. , 2004, Haematologica.

[36]  D. Denning,et al.  Epidemiology and pathogenesis of systemic fungal infections in the immunocompromised host. , 1991, The Journal of antimicrobial chemotherapy.